Review article · 2026 · Open access
Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections
Cureus, 18(5), e108749 · Published 12 May 2026 · DOI 10.7759/cureus.108749
In brief
“Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections” is a 2026 review article by Luke Cho and 3 co-authors, published in Cureus. OpenAlex counts 0 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at Cureus.
- Citations
- 0
- References
- 43
- Authors
- 4
Abstract
Phage therapy, the therapeutic use of bacteriophages for multi-drug resistant bacterial infections, is an understudied treatment approach that has been receiving increased interest in recent years. With multiple different treatment strategies (e.g., oral vs. intravenous (IV)) as well as varying types of bacteriophage combinations (phage cocktails) that are possible, the effectiveness of these phage cocktails on certain bacterial infections, as well as overall safety, is in question. This systematic review aims to analyze current evidence on the efficacy and safety outcomes of bacteriophage therapy for resistant bacterial infections. A systematic search of PubMed, Embase, and Scopus was conducted to investigate clinical studies following guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). Included studies addressed the efficacy of phage cocktails in bacterial-resistant infections with a secondary focus on safety and adverse events. Two independent reviewers assessed randomized controlled studies using the Cochrane Risk-of-Bias 2 (ROB-2) tool and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool. The three randomized controlled studies demonstrated low risk of bias, while the non-randomized controlled study showed a serious risk of bias. Patient outcomes and adverse events were narratively synthesized due to heterogeneity across study populations, pathogens, and treatment protocols. In total, only four studies met the scope of this review, which significantly limits the interpretation of the results. Two studies focused on Pseudomonas aeruginosa infections, while one study looked at Mycobacterium spp., and another study examined Helicobacter pylori infections known to hold some antibiotic resistance. Phage administration ranged from topical/aerosol for the P. aeruginosa infections, IV/aerosol for Mycobacterium spp., and oral for H. pylori. The two studies on P. aeruginosa demonstrated statistically significant reductions in bacterial presence, while the other two studies did not demonstrate statistically significant results. Regarding safety, no study reported any statistically significant severe adverse events. Two trials provided data on less severe adverse events, which were not statistically significant compared to the comparison groups. The trends synthesized from this study are limited by disease and therapeutic heterogeneity, sample size, and different treatment durations. Phage therapy shows early promise for drug-resistant infections, particularly P. aeruginosa, with a favorable safety profile. However, due to therapeutic and disease heterogeneity, small sample sizes, and variable treatment durations, larger dedicated trials are needed.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cho, L., Chang, H., Cho, E., & Rajagopal, T. (2026). Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections. Cureus, 18(5), e108749. https://doi.org/10.7759/cureus.108749
MLA 9
Cho, Luke, et al. “Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections.” Cureus, vol. 18, no. 5, 2026, p. e108749. https://doi.org/10.7759/cureus.108749.
Chicago
Cho, Luke, Hannah Chang, Evan Cho, and Thiru Rajagopal. 2026. “Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections.” Cureus 18 (5): e108749. https://doi.org/10.7759/cureus.108749.
Harvard
Cho, L. et al. (2026) ‘Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections’, Cureus, 18(5), p. e108749. doi:10.7759/cureus.108749.
IEEE
L. Cho, H. Chang, E. Cho, and T. Rajagopal, “Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections,” Cureus, vol. 18, no. 5, p. e108749, 2026, doi: 10.7759/cureus.108749.
BibTeX
@article{cho2026efficacy,
title = {{Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections}},
author = {Cho, Luke and Chang, Hannah and Cho, Evan and Rajagopal, Thiru},
journal = {Cureus},
year = {2026},
volume = {18},
number = {5},
pages = {e108749},
doi = {10.7759/cureus.108749},
url = {https://doi.org/10.7759/cureus.108749}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
- phage therapy
- phage cocktail
- antibiotic-resistant bacterial infections
- Pseudomonas aeruginosa infection
- mycobacterial infection
- Helicobacter pylori infection
- treatment efficacy
- adverse events
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Cho, L., Chang, H., Cho, E., & Rajagopal, T. (2026). Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections. Cureus, 18(5), e108749. https://doi.org/10.7759/cureus.108749
How many times has this paper been cited?
0 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Cureus.
Who wrote this paper?
Luke Cho, Hannah Chang, Evan Cho, Thiru Rajagopal.
What is the DOI of this paper?
10.7759/cureus.108749. The permanent link is https://doi.org/10.7759/cureus.108749.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.